Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received four drug license suspension orders across different states. The suspensions are for stores in Telangana (Kurnool – 7 days), Tamil Nadu (Trichy – 3 days), and Karnataka (Hubli – 1 day and 3 days). The actions were taken under Rule 65 of the Drugs and Cosmetics Act, 1940 by respective state drug control authorities. The total potential revenue loss from these four suspensions is approximately Rs 6.07 lakhs. The orders were received on June 17, 2025, and the disclosure was made on June 18, 2025.
The financial impact is very small (around Rs 6 lakhs) and limited to four individual stores, so this is unlikely to materially affect Medplus's overall operations or stock price. It signals routine regulatory compliance issues that large pharmacy chains occasionally face.